Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) |
| |
| Authors: | M. Jensen U. Winkler O. Manzke V. Diehl A. Engert |
| |
| Affiliation: | Department I for Internal Medicine, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50931 K?ln, Germany Tel.: 02?21/4?78/66?28, Fax: 02?21/4?78/35?31, DE
|
| |
| Abstract: | Summary In this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome after administration of the human anti-CD20 antibody IDEC-C2B8 (RITUXIMAB) in standard dose of 375 mg/m2. IDEC-C2B8 has been demonstrated to have only mild and tolerable side effects in patients with follicular lymphoma. In these trials patients with lymphocytosis >5000/μl were excluded. Physicians must be aware of this hitherto unreported phenomenon in patients with high CD20-positive blood counts. Received: July 9, 1998 / Accepted: July 20, 1998 |
| |
| Keywords: | Chronic lymphocytic leukemia IDEC-C2B8 Rituximab Tumor lysis syndrome Immunotherapy |
| 本文献已被 SpringerLink 等数据库收录！ |
